MAX SENNA MANO
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
conferenceObject Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region(2014) MARTINEZ-MESA, Jeovany; WERUTSKY, Gustavo; MICHIELS, Stefan; SAMPAIO-FILHO, Carlos Alberto; DUENAS, Alfonso; ZARBA, Juan Jose; MANO, Max S.; VILLARREAL-GARZA, Cynthia Mayte; GOMEZ, Henry Leonidas; BARRIOS, Carlos H.- Metaplastic breast cancer: A single-institution experience.(2016) SILVA, Aumilto Augusto; LINCK, Rudinei Diogo Marques; LIMA, Julianne Maria da Silva; MATUTINO, Adriana Reis Brandao; SILVA, Saulo Brito; VICENTINI, Maria Fernanda; FELIZOLA, Marcelo; GAGLIATO, Debora De Melo; HOFF, Paulo Marcelo; MANO, Max S.
- Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.(2019) SCHNEEWEISS, Andreas; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter von; MANO, Max S.; UNTCH, Michael; HUANG, Chiun-Sheng; RASTOGI, Priya; CONTE, Pier Franco; D'HONDT, Veronique; REDONDO, Andres; STAMATOVIC, Ljiljana; BONNEFOI, Herve R.; SALGUERO, Hugo Raul Castro; FISCHER, Hans Holger; WAHL, Tanya A.; SONG, Chunyan; BLOTNER, Steven; TRASK, Peter; GEYER, Charles E.
conferenceObject A randomized, open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801/EGF111792)(2012) GOMEZ, Henry Leonidas; NECIOSUP, Silvia P.; TOSELLO, Celia; XAVIER, Patricia; NASCIMENTO, Yeni Neron do; FANELLI, Marcelo; ISMAEL, Gustavo; BINES, Jose; SAMPAIO, Carlos; LERZO, Guillermo Luis; CAPO, Adolfo Miguel; MANO, Max S.; FEIN, Luis; WERUTSKY, Gustavo; BARRIOS, Carlos H.Background: Lapatinib-capecitabine is approved for the treatment of ErbB2-amplified metastatic breast cancer (MBC) after failure to anthracyclines, taxanes and trastuzumab. GLICO-0801 evaluates different lapatinib-based chemotherapy combinations as 1st/2nd line treatment for ErbB2 amplified MBC progressing after taxane treatment. We present the results of a planned safety interim analysis. Methods: This is an open-label, randomized, international, phase II trial exploring lapatinib (L) 1250mg qd in combination with capecitabine 2000mg/m2 d 1-14 (Arm A) or vinorelbine 25mg/m2 d 1 and 8 (Arm B) or gemcitabine 1000mg/m2 d 1 and 8 (Arm C). Primary objective is to determine the clinical benefit rate (defined as CR+PR+SD for ≥24 weeks). This trial is registered at www.clinicaltrials.gov number: NCT01050322 Results: The first83 randomized patients (pts) (Arm A=29, B=28 and C=26) were included in this analysis. Of them, 65 (78%) have discontinued therapy with mean number of cycles of 4.7, 6.2 and 7.5 in arms A, B and C respectively. Eighteen (21%) pts are still on treatment. Median age was 52y (29-84); 80 pts (96%) had PS 0-1; 51 (61%) were postmenopausal. Fifty-six pts (67%) had visceral metastasis, 52 (63%) were treated as 2nd line therapy and 36 (43%) had received prior trastuzumab. Most reported adverse events (AE) (87%) were grade 1-2. The most common AE (any grade) in arm A: diarrhea 72%, hand-foot syndrome 45%, vomiting 39%, anemia 36%; in arm B: diarrhea 75%, neutropenia 68%, nausea 43%, vomiting 39%; in arm C: diarrhea 72%, neutropenia 60%, anemia 44%, increase in ALT 44%. The most frequent serious AE reported in arm A: diarrhea in 3 pts (10%) and thrombocytopenia in 2 pts (7%); in arm B: febrile neutropenia in 2 pts (7%) and in arm C: sepsis in 1 pt (4%). There was one toxic death related to chemotherapy in arm C. Conclusions: There were no unexpected toxicities so far in this trial with most AEs being mild to moderate and manageable. This interim analysis supports the continuation of the study.conferenceObject Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.(2020) DENKERT, Carsten; LAMBERTINI, Chiara; FASCHING, Peter A.; POGUE-GEILE, Katherine L.; MANO, Max S.; UNTCH, Michael; WOLMARK, Norman; HUANG, Chiung-Sheng; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter Von; GEYER, Charles E.; BOULET, Thomas; SONG, Chunyan; PHILLIPS, Gail Lewis; NOWICKA, Malgorzata; HAAS, Sanne de; BASIK, MarkconferenceObject Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer(2014) CAMERON, David A.; SPECTOR, Neil; CORTES, Javier; MANO, Max S.; CANON, Jean-Luc Re; HICKISH, Tamas; VANDAT, Linda T.; KIM, Sung-Bae; GOMEZ, Henry Leonidas; EL-HARIRY, Iman; VUKOVIC, Vojislav M.; SHELDON, Emily H.; PEREZ, Edith A.; AWADA, AhmadconferenceObject Febrile neutropenia risk with adjuvant TC (docetaxel and cyclophosphamide) regimen: Experience of Brazilian cancer centers(2014) SANTOS, Joao Paulo Velloso Medrado; GAGLIATO, Debora De Melo; COSSETTI, Rachel Jorge Dino; GIMENEZ, Rodrigo Darouche; MANO, Max S.conferenceObject Discordance between Oncotype Dx and Saint Gallen criteria, Adjuvant!, NCCN 2011 guidelines, and initial physician treatment recommendation(2012) PEREIRA, Allan Andresson Lima; SANTINI, Fernando Costa; SHIMADA, Andrea Kazumi; NASCIMENTO, Ellen Caroline; KATZ, Artur; MANO, Max S.Background: The Oncotype Dx recurrence score (RS) assay quantifies the risk of distant recurrence (rDR) and its use has increased despite the lack of prospective studies. Methods: This is a cross sectional retrospective study of consecutive patients (PTS) from our institution with histologically confirmed invasive breast cancer who underwent surgery with curative intent and in whom Oncotype was performed. The main objectives were to compare (1) the predicted rDR by RS and Adjuvant! (2) Risk allocation by RS and St Gallen Criteria, (3) chemotherapy indication according to RS results and NCCN guidelines and (4) to evaluate the impact of RS results on the recommendation of adjuvant chemotherapy (aCT). Results: Between October/2006-June/2011, 74 PTS were evaluated. Forty seven (63,5%) were EC IA and all had estrogen receptor positive; axillary lymph node involvement was seen in 19 PTS (13 micro and 6 macrometastasis). The rDR by RS was low in 50 PTS (67%), intermediate in 19 (26%) and high in 5 (7%). According to Saint Gallen, 7 (9%), 51 (69%) and 14 PTS (19%) were classified as low, intermediate and high risk, respectively. There was a statistical significant discordance between risk allocation according to RS and Saint Gallen (Kappa coefficient=-0.002; p=0.971). Among the 55 node-negative PTS, there was also a statistical significant discordance between the predicted average rDR, obtained from Oncotype, and Adjuvant! with median risk of 8,5% vs 15,7%, respectively (p = 0.00001 rank sum Mann Whitney test). The NCCN 2011 would have indicated aCT to 62 PTS. Among 55 classified as low and high risk by RS, the NCCN would have indicated aCT to 46 PTS. In other words, 89% (41) of PTS who would receive aCT by NCCN were classified as low risk by RS, with a statistically significant discordance (Kappa coefficient=0.035, p=0.328). Conclusions: Oncotype changed the medical management in 28 (55%) of 51 PTS in which the initial intention of the physician was known. Of these, 93% were spared aCT. We found no statistical significant concordance among the Saint Gallen, Adjuvant! or NCCN guidelines with Oncotype Dx. The rDR may be overestimated by clinicopathological-based classifications.conferenceObject Feasibility of two schedules of weekly paclitaxel as (neo)adjuvant treatment for patients (PTS) with HER2-negative breast cancer (BC) in the Brazilian community setting(2012) SANTANA, Iuri Amorim; OLIVEIRA, Julia Andrade De; AMARAL, Alan Alves; TESTA, Laura; LANDEIRO, Luciana Garcia; COSTA, Romulo Leopoldo de Paula; HAJIME, Marcelo; FERRARI, Marcela Simonis Martins; PETRY, Vanessa; COHN, Daniela J. B. Heinemann; HOFF, Paulo M.; MANO, Max S.conferenceObject Metronomic chemotherapy (MC) in the neoadjuvant setting: Results of two parallel feasibility trials in patients (pts) with HER2 positive (HER2+) and negative (HER2-) locally advanced breast cancer (LABC) (Traq-Me and TAME)(2012) PETRY, Vanessa; LEAL, Alessandro; ARAI, Roberto J.; MARINHO, Simone; PAIVA, Marcelo; PIATO, Jose R.; ROSA, Marcio; HOFF, Paulo M.; MANO, Max S.